Evaluating the Efficacy and Safety of Xalost S in Glaucoma Patients.
Status:
Unknown status
Trial end date:
2020-02-01
Target enrollment:
Participant gender:
Summary
In patients with Glaucoma, Xalost S or Xalatan or Taflotan-S are administered for 12 weeks.
After 12 weeks, among them, Xalatan administration group are switched to Xalost S or
Taflotan-S. Extension study period is 8 weeks.
To compare effect (ocular surface damage) and safety of preservative-free
Latanoprost/Tafluprost to Benzalkonium chloride-preserved Latanoprost in primary open angle
glaucoma or normal tension glaucoma.